MO - Altria Group, Inc.
50.99 +0.10 (0.20%)
After hours: 6:23PM EST
| Previous Close | 52.35 |
| Open | 52.36 |
| Bid | 50.99 x 3200 |
| Ask | 51.00 x 800 |
| Day's Range | 50.69 - 52.44 |
| 52 Week Range | 50.69 - 74.38 |
| Volume | 10,671,452 |
| Avg. Volume | 8,734,171 |
| Market Cap | 95.625B |
| Beta (3Y Monthly) | -0.14 |
| PE Ratio (TTM) | 9.04 |
| EPS (TTM) | 5.63 |
| Earnings Date | Jan 30, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | 3.20 (6.07%) |
| Ex-Dividend Date | 2018-12-24 |
| 1y Target Est | 64.49 |
- CNBC Videos•20 minutes ago
Final Trades: LOW, MO & more
The "Fast Money" traders share their final trades of the day, including Lowe's, Altria Group, the XLU utilities ETF and Target.
- Investing.com•1 hour ago
Altria Falls 3%
Investing.com - Altria (NYSE:MO) fell by 3.02% to trade at $50.77 by 15:25 (20:25 GMT) on Tuesday on the NYSE exchange.
- Investor's Business Daily•2 hours ago
Citron Boosts Shorted Pot Stock: Industry Dynamics Have Just Changed
One of Wall Street's most notorious short-sellers — and a onetime skeptic of marijuana stocks — is giving Canadian cannabis producer Aphria a big assist.
- Market Realist•4 hours ago
Philip Morris Stock Tanks on Credit Suisse Downgrade
Today, Reuters reported that Credit Suisse downgraded Philip Morris International (PM) from “neutral” to “underperform” and lowered its price target to $74 from $92. The new price target represents a fall of 9.1% from the company’s December 17 closing price of $81.40. Among the 19 analysts who follow Philip Morris, 52.6% recommend a “buy,” 36.8% recommend a “hold,” and 10.5% recommend a “sell.” On average, analysts have given the stock a price target of $93.25, which represents an upside potential of 14.6% from its closing price on December 17.
- InvestorPlace•6 hours ago
Check Your Risk Tolerance Before Inhaling Aphria Stock
Although it has risen from recent lows, the pain for Aphria (NYSE:APHA) stock continues. With the credibility of Aphria’s management called into question by short-seller research reports, APHA has now fallen below Cronos (NASDAQ:CRON) in market cap. With APHA trading at a much lower valuation than its peers, the case for a risky contrarian play in Aphria stock only grows stronger.
- InvestorPlace•8 hours ago
What to Expect From Cronos Stock In the Latest Pot Hype Cycle
Marijuana stocks like Cronos Group (NASDAQ:CRON) stock have spent 2018 in the hype cycle. The hype cycle is a term common to technology investors. Now, just as things settle down, Altria (NYSE:MO), formerly the U.S. unit of Philip Morris, is paying $1.8 billion to get 45% of Cronos, a medical marijuana company based in Canada.
- Zacks•8 hours ago
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
The Zacks Analyst Blog Highlights: McDonald???s, AbbVie, Altria, Wells Fargo and Disney
- Zacks•9 hours ago
Can Altria (MO) Rebound From a Terrible 2018?
Stringent FDA regulations have led to fading cigarette sales that are plaguing the performance of Altria. Nevertheless, growth in RRPs looks encouraging.
- Motley Fool•11 hours ago
3 Stocks Poised for Huge Growth Over the Next Decade
Cronos Group, Welltower, and Zscaler will ride the next supertrend wave.
- InvestorPlace•12 hours ago
Cronos Stock Should Be a Buy — Just Not Yet
Cronos executed a potentially transformative deal with tobacco giant Altria (NYSE:MO). Indeed, I’m somewhat surprised by the reaction, in terms of both Cronos stock and pot stocks on the whole. As rumors of a deal flew earlier this month, I wrote that an executed agreement would be transformative for CRON stock, and the industry.
- Zacks•yesterday
Altria (MO) Stock Moves -0.72%: What You Should Know
Altria (MO) closed the most recent trading day at $52.35, moving -0.72% from the previous trading session.
- Investopedia•yesterday
Which Company Is Behind Popular E-Cigarette, JUUL?
- MarketWatch•yesterday
Makers of flavored e-cigarettes face ‘a make-or-break year’ in Washington, analyst says
“2019 will be a make-or-break year for alternative tobacco product manufacturers to regain control of the flavors debate,” says Stefanie Miller of Height Capital Markets in a note Friday.
- Motley Fool•yesterday
3 Top Dividend Stocks With Yields Over 4%
These three stocks offer big yields but trade at low valuations.
- InvestorPlace•yesterday
Why Tilray Stock Shouldn’t Take the Heat for Aphria’s Problem
You can never take anything for granted in the legal-cannabis sector, and Tilray (NASDAQ:TLRY) offered the latest cautionary tale. After several trading sessions stabilizing around the $100 level suggested relative normalization, Tilray stock entered a full-blown meltdown. Since the start of the week, TLRY has hemorrhaged over 25% of market value.
- Motley Fool•2 days ago
Should You Buy Philip Morris International for Its 5% Dividend Yield?
Has the tobacco giant become an undervalued income investment?
- Motley Fool•2 days ago
Better Marijuana Stock: Cronos Group vs. Scotts Miracle-Gro
Which stock wins in a matchup between a high-flying Canadian marijuana producer and a beaten-down top supplier to the U.S. cannabis industry?
- Motley Fool•2 days ago
5 Things That Really Matter When Investing in Marijuana Stocks
Hint: Peak production potential isn't one of them.
- Motley Fool•3 days ago
Better Buy: Canopy Growth vs. Cronos Group
Big deals for both of these marijuana producers have excited investors. But which stock will be the bigger winner down the road?
- Motley Fool•3 days ago
3 Marijuana Stocks That Could Land a Big-Name Partner in 2019
Cannabis dealmaking is likely to continue into the new year.
- Motley Fool•3 days ago
Better Buy: PepsiCo vs. Altria
Which of these dividend stocks is the best choice for your portfolio?
Motley Fool•4 days agoThis Small-Cap Cannabis Stock Is Up Big in a Down Market. Here's Why.
Medical Marijuana's stock has started to heat up. Here's why.
- Kiplinger•4 days ago
12 Stocks You Should Never Sell
Hopping in and out of stocks tends to do more harm than good to your portfolio. Fortunately, most of the time, investors are content to sit back and let time do the heavy lifting. Every now and then, however, an uninterrupted market-wide rally (such as the one we saw in 2017) followed by a couple of major corrections (such as the ones we've seen in 2018) inspires a more active approach. Buying every dip last year was a bulletproof strategy; steering clear of this year's big dips would've left most investors far better off. But broadly speaking, investors shouldn't embrace that short-term mindset. Buy-and-hold is a time-tested strategy that helps investors avoid trying to time the market (which even experts can't reliably do) and making poor emotional decisions. With that as a backdrop, here are a dozen stocks to never sell. Many buy-and-holders are looking to reset their portfolios as the new year begins. If you hold any of the stocks, don't stop ... and if you're looking to buy, be ready to commit. Each company has plenty to success that their history of success should continue for years to come. And each operates in an industry that won't go away anytime soon. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond
- IPO-Edge.com•4 days ago
High Times Rolls Up Another Conference with BIG Show Acquisition – More M&A in Store?
High Times Purchases B2B Conference Operator Buyers Industry Guide By John Jannarone The parent of High Times magazine has acquired a major cannabis event operator just days after clearing most of the debt from its balance sheet, a likely sign of more deals to come. High Times Holding Corp, which operates the renowned Cannabis Cup […]
- IPO Edge•4 days ago
High Times Rolls Up Another Conference with BIG Show Acquisition – More M&A in Store?
High Times Purchases B2B Conference Operator Buyers Industry Guide By John Jannarone The parent of High Times magazine has acquired a major cannabis event operator just days after clearing most of the debt from its balance sheet, a likely sign of more deals to come. High Times Holding Corp, which operates the renowned Cannabis Cup […]
